Overlapping Region of p53/Wrap53 Transcripts: Mutational Analysis and Sequence Similarity with microRNA-4732-5p

  • Published : 2013.06.30


Background: Although the majority of investigations concerned with TP53 and its protein have focused on coding regions, recently a set of studies highlighted significant roles of regulatory elements located in p53 mRNA, especially 5'UTR. The wrap53${\alpha}$ transcript is one of those that acts as a natural antisense agent, forming RNA-RNA hybrids with p53 mRNA and protecting it from degradation. Materials and Methods: In this study, we focused on the mutation status of exon $1{\alpha}$ of the WRAP53 gene (according to exon 1 of p53) in 160 breast tumor tissue samples and conducted a bioinformatics search for probable miRNA binding site in the p53/wrap53 overlapping region. Mutations were detected, using single stranded conformation polymorphism (SSCP) and sequencing. We applied the miRBase database for prediction of miRNAs which target overlapping region of p53/wrap53 transcripts. Results: Our results showed all samples to have wild type alleles in exon 1 of TP53 gene. We could detect a novel and unreported intronic mutation (IVS1+56, G>C) outside overlapping regions of p53/wrap53 genes in breast cancer tissues and also predict the presence of a binding site for miR-4732-5p in the 5'UTR of Wrap53 mRNA. Conclusions: From our findings we propose designing further studies focused on overexpression of miRNA-4732-5p and introducing different mutations in the overlapping region of wrap53 and p53 genes in order to study their effects on p53 and its ${\Delta}N$ isoform (${\Delta}$40p53) expression. The results may provide new pieces in the p53 targeting puzzle for cancer therapy.


  1. Alonso S, Izagirre N, Lopez S, et al (2010). The diversity profile of TP53 is influenced by positive selection on the immediately upstream locus WDR79. Hum Hered, 69, 34-44.
  2. Aylon Y, Oren M (2007). New plays in the p53 theater. Current Opinion in genetics Development, 21, 86-92.
  3. Bienz B, Zakut-Houri R, Givol D, Oren M (1984). Analysis of the gene coding for the murine cellular tumor antigen p53. EMBO J, 3, 2179-2183.
  4. Bienz-Tadmor B, Zakut-Houri R, Libresco S, et al (1985). The 5' region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. EMBO J, 4, 3209-13.
  5. Bug M, Dobbelstein M (2011). Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms. Oncogene, 30, 3612-3624.
  6. Chatterjee S, Pal JK (2009). Role of 5' and 3' untranslated regions of mRNAs in human diseases. Biol Cell, 101, 251-62.
  7. Chen F, Wang W, El-Deiry WS (2010). Current strategies to target p53 in cancer. Biochem Pharmacol, 80, 724-30.
  8. Chen J, Kastan MB (2010). 5'-3'-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. Genes Dev, 24, 2146-56.
  9. Crocitto LE, Henderson BE, Coetzee GA (1997). Identification of two germline point mutations in the 5'UTR of the androgen receptor gene in men with prostate cancer. J Urol, 158, 1599-601.
  10. Crowe ML, Wang XQ, Rothnagel JA (2006). Evidence for conservation and selection of upstream open reading frames suggests probable encoding of bioactive peptides. BMC Genomics, 26, 7-16.
  11. Editorial (2010). Drug discovery in the p53 field. Seminars Cancer Biology, 20, 1-2.
  12. Faghihi MA, Zhang M, Huang J, et al (2010). Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Bio, 11, 56.
  13. Farnebo M (2009). Wrap53, a novel regulatory of p53. Cell Cycle, 8, 2343-6.
  14. Farnebo M, Bykov V JN, Wiman K (2010). The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Communications, 396, 85-9.
  15. Gochhait S, Bukhari SIA, Bairwa N, et al (2007). Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res, 9, 71.
  16. Griffiths-Jones S, Grocock RJ, Van Dongen S, Bateman A, Enright AJ (2006a). The microRNA sequence database. Methods Molecular Biology, 342, 129-38.
  17. Griffiths-Jones S, Grocock RJ, van Dongen S, et al (2006b). miRBase: microRNA sequences, targets, and gene nomenclature. Nucleic Acids Res, 34,140-4.
  18. Grover R, Sharathchandra A, Ponnuswamy A, et al (2011). Effect of mutations on the p53 IRES RNA structure Implications for de-regulation of the synthesis of p53 isoforms. RNA Biology, 8, 132-42.
  19. Khan D, Sharathchandra A, Ponnuswamy A, et al (2012). Effect of a natural mutation in the 5' untranslated region on the translational control of p53 mRNA. Oncogene, [Epub ahead of print].
  20. Le MT, Teh C, Shyh-Chang N, et al (2009). MicroRNA 125b is a novel negative regulator of p53. Genes Dev, 23, 862-76.
  21. Levine AJ, Oren M (2009). The first 30 years of p53: growing ever more complex. Nature Reviews Cancer, 9, 749-58
  22. Mahmoudi S, Henriksson S, Corcoran M, et al (2009). Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Molecular Cell, 33, 462-71.
  23. Olivier M, Petitjean A, Marcel V, et al (2009). Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Therapy, 16, 1-12.
  24. Persson H, Kvist A, Rego N, et al (2011). Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res, 71, 78-86.
  25. Signori E, Bagni C, Papa S, et al (2001). A somatic mutation in the 5'UTR of the BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency. Oncogene, 20, 4596-600.
  26. Takagi M, Absalon MJ, McLure KG, Kastan MB (2005). Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell, 123, 49-63.
  27. Vilborg A, Wilhelm A, Wiman K (2010). Regulation of tumor suppressor p53 at the RNA level. J MOL MED, 88, 645-52.
  28. Yuan JM, Li XD, Liu ZY, et al (2011). Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev, 12, 3465-9.
  29. Zhang H, Wang D, Mahmoudi S, et al (2012). WRAP53 is an independent prognostic factor in rectal cancer - a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients. BMC Cancer, 12, 294.
  30. Zhang Y, Gao JS, Tang X, et al (2009). MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett, 583, 3725-30

Cited by

  1. Lack of Association of Intron 3 16 bp Polymorphism of TP53 with Breast Cancer among Iranian-Azeri Patients vol.15, pp.6, 2014,
  2. Association of TP53 PIN3 polymorphism with breast cancer in Moroccan population vol.35, pp.12, 2014,
  3. Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia vol.390, pp.1-2, 2014,
  4. The TP53 intron 6 G13964C Polymorphism and Risk of Thyroid and Breast Cancer Development in the Iranian Azeri Population vol.16, pp.7, 2015,
  5. Identification of microRNAs in Nipple Discharge as Potential Diagnostic Biomarkers for Breast Cancer vol.22, pp.S3, 2015,
  6. Possible tumor suppressive role of the miR-144/451 cluster in esophageal carcinoma as determined by principal component regression analysis vol.14, pp.4, 2016,
  7. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes vol.37, pp.10, 2016,
  8. Bioinformatics analysis of dysregulated microRNAs in the nipple discharge of patients with breast cancer vol.13, pp.5, 2017,
  9. Changes in the Expression of Circulating microRNAs in Systemic Lupus Erythematosus Patient Blood Plasma After Passing Through a Plasma Adsorption Membrane vol.22, pp.3, 2018,